Logo

Jazz's Vyxeos (daunorubicin and cytarabine liposome) for Injection Receives Health Canada Approval for the Treatment of High-risk Acute Myeloid Leukemia

Share this

Jazz's Vyxeos (daunorubicin and cytarabine liposome) for Injection Receives Health Canada Approval for the Treatment of High-risk Acute Myeloid Leukemia

Shots:

  • The approval is based on the results from a P-III study that involves assessing Vyxeos (IV infusion) vs a current conventional treatment group in 309 adult patients aged 60-75 yrs. with newly diagnosed t-AML or AML-MRC
  • The study met its 1EPs i.e the therapy demonstrates the improvement in OS; m-OS (9.6 vs 6.0 mos.)
  • Vyxeos (daunorubicin & cytarabine liposome) is a 1st CT treatment option for adults with newly diagnosed t-AML or AML with AML-MRC while the therapy has developed with the company's CombiPlex platform to facilitate the design & rapid evaluation of various combinations of therapies

  Ref: Jazz Pharmaceuticals | Image: Jazz Pharmaceuticals

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions